Preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation and flutter
Aim. To compare the efficacy and safety of chemical cardioversion (CCV) with refralon and amiodarone in patients with paroxysmal atrial fibrillation and flutter (AF/AFL).Material and methods. Fifty five patients (mean age, 65±11 years) with paroxysmal AF/AFL were included. All patients underwent a...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2023-05-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/3527 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839577785819987968 |
|---|---|
| author | D. A. Gagloeva Kh. M. Dzaurova M. A. Zelberg N. Yu. Mironov Yu. A. Yuricheva S. F. Sokolov M. A. Krymukova A. I. Salpagarova L. O. Dulaev D. V. Pevzner S. P. Golitsyn |
| author_facet | D. A. Gagloeva Kh. M. Dzaurova M. A. Zelberg N. Yu. Mironov Yu. A. Yuricheva S. F. Sokolov M. A. Krymukova A. I. Salpagarova L. O. Dulaev D. V. Pevzner S. P. Golitsyn |
| author_sort | D. A. Gagloeva |
| collection | DOAJ |
| description | Aim. To compare the efficacy and safety of chemical cardioversion (CCV) with refralon and amiodarone in patients with paroxysmal atrial fibrillation and flutter (AF/AFL).Material and methods. Fifty five patients (mean age, 65±11 years) with paroxysmal AF/AFL were included. All patients underwent a preliminary examination to rule out contraindications to CCV. Further, patients were randomized into groups of refralon (n=30) and amiodarone (n=28), respectively. CCV with refralon was carried out as follows: administration in doses of 5-5-10-10 µg/kg at intervals of 15 minutes. Patients of the second group were intravenously injected with amiodarone at a dose of 5 mg/kg of body weight for 20-60 minutes, depending on the drug tolerability. If AF/AFL persists after 60 minutes, infusion of amiodarone 100 mg/hour until restoration of sinus rhythm (SR) or reaching a dose of 1200 mg/day. Treatment efficacy was assessed by SR recovery, absence of AF/AFL recurrence, and arrhythmia relief time, and safety was assessed by detection of ventricular arrhythmogenic effects, bradyarrhythmias, blood pressure reduction, and QT interval prolongation. The follow-up period lasted 24 hours.Results. SR was restored in 96,7% (n=29) of patients in the refralon group, of which 56,7% (n=17) after a dose of 5 mcg/kg. In the amiodarone group, SR was restored in 57,1% (n=16) of patients (p<0,001). The arrhythmia relief time in the refralon group was 14 [7;23] min, while in the amiodarone group — 150 [82;240] min (p<0,001). There were no significant differences in the incidence of bradyarrhythmias, lowering blood pressure, and QT prolongation in the groups.Conclusion. Refralon demonstrates a higher efficiency and lower time to AF/AFL relief compared with amiodarone, while in most patients, SR recovery occurs after the administration of the lowest doses, which ensures CCV safety. |
| format | Article |
| id | doaj-art-9421170c3fc74df083e12f23e2bc4e63 |
| institution | Matheson Library |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2023-05-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-9421170c3fc74df083e12f23e2bc4e632025-08-04T12:50:29Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252023-05-0122410.15829/1728-8800-2023-35272689Preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation and flutterD. A. Gagloeva0Kh. M. Dzaurova1M. A. Zelberg2N. Yu. Mironov3Yu. A. Yuricheva4S. F. Sokolov5M. A. Krymukova6A. I. Salpagarova7L. O. Dulaev8D. V. Pevzner9S. P. Golitsyn10E.I. Chazov National Medical Research Center for CardiologyE.I. Chazov National Medical Research Center for CardiologyE.I. Chazov National Medical Research Center for CardiologyE.I. Chazov National Medical Research Center for CardiologyE.I. Chazov National Medical Research Center for CardiologyE.I. Chazov National Medical Research Center for CardiologyE.I. Chazov National Medical Research Center for CardiologyE.I. Chazov National Medical Research Center for CardiologyE.I. Chazov National Medical Research Center for CardiologyE.I. Chazov National Medical Research Center for CardiologyE.I. Chazov National Medical Research Center for CardiologyAim. To compare the efficacy and safety of chemical cardioversion (CCV) with refralon and amiodarone in patients with paroxysmal atrial fibrillation and flutter (AF/AFL).Material and methods. Fifty five patients (mean age, 65±11 years) with paroxysmal AF/AFL were included. All patients underwent a preliminary examination to rule out contraindications to CCV. Further, patients were randomized into groups of refralon (n=30) and amiodarone (n=28), respectively. CCV with refralon was carried out as follows: administration in doses of 5-5-10-10 µg/kg at intervals of 15 minutes. Patients of the second group were intravenously injected with amiodarone at a dose of 5 mg/kg of body weight for 20-60 minutes, depending on the drug tolerability. If AF/AFL persists after 60 minutes, infusion of amiodarone 100 mg/hour until restoration of sinus rhythm (SR) or reaching a dose of 1200 mg/day. Treatment efficacy was assessed by SR recovery, absence of AF/AFL recurrence, and arrhythmia relief time, and safety was assessed by detection of ventricular arrhythmogenic effects, bradyarrhythmias, blood pressure reduction, and QT interval prolongation. The follow-up period lasted 24 hours.Results. SR was restored in 96,7% (n=29) of patients in the refralon group, of which 56,7% (n=17) after a dose of 5 mcg/kg. In the amiodarone group, SR was restored in 57,1% (n=16) of patients (p<0,001). The arrhythmia relief time in the refralon group was 14 [7;23] min, while in the amiodarone group — 150 [82;240] min (p<0,001). There were no significant differences in the incidence of bradyarrhythmias, lowering blood pressure, and QT prolongation in the groups.Conclusion. Refralon demonstrates a higher efficiency and lower time to AF/AFL relief compared with amiodarone, while in most patients, SR recovery occurs after the administration of the lowest doses, which ensures CCV safety.https://cardiovascular.elpub.ru/jour/article/view/3527atrial fibrillationparoxysmal typerefralonamiodaronechemical cardioversionclass iii antiarrhythmic drugs |
| spellingShingle | D. A. Gagloeva Kh. M. Dzaurova M. A. Zelberg N. Yu. Mironov Yu. A. Yuricheva S. F. Sokolov M. A. Krymukova A. I. Salpagarova L. O. Dulaev D. V. Pevzner S. P. Golitsyn Preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation and flutter Кардиоваскулярная терапия и профилактика atrial fibrillation paroxysmal type refralon amiodarone chemical cardioversion class iii antiarrhythmic drugs |
| title | Preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation and flutter |
| title_full | Preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation and flutter |
| title_fullStr | Preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation and flutter |
| title_full_unstemmed | Preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation and flutter |
| title_short | Preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation and flutter |
| title_sort | preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation and flutter |
| topic | atrial fibrillation paroxysmal type refralon amiodarone chemical cardioversion class iii antiarrhythmic drugs |
| url | https://cardiovascular.elpub.ru/jour/article/view/3527 |
| work_keys_str_mv | AT dagagloeva preliminaryresultsofaprospectiverandomizedstudycomparingtheefficacyandsafetyofrefralonandamiodaroneincardioversioninpatientswithparoxysmalatrialfibrillationandflutter AT khmdzaurova preliminaryresultsofaprospectiverandomizedstudycomparingtheefficacyandsafetyofrefralonandamiodaroneincardioversioninpatientswithparoxysmalatrialfibrillationandflutter AT mazelberg preliminaryresultsofaprospectiverandomizedstudycomparingtheefficacyandsafetyofrefralonandamiodaroneincardioversioninpatientswithparoxysmalatrialfibrillationandflutter AT nyumironov preliminaryresultsofaprospectiverandomizedstudycomparingtheefficacyandsafetyofrefralonandamiodaroneincardioversioninpatientswithparoxysmalatrialfibrillationandflutter AT yuayuricheva preliminaryresultsofaprospectiverandomizedstudycomparingtheefficacyandsafetyofrefralonandamiodaroneincardioversioninpatientswithparoxysmalatrialfibrillationandflutter AT sfsokolov preliminaryresultsofaprospectiverandomizedstudycomparingtheefficacyandsafetyofrefralonandamiodaroneincardioversioninpatientswithparoxysmalatrialfibrillationandflutter AT makrymukova preliminaryresultsofaprospectiverandomizedstudycomparingtheefficacyandsafetyofrefralonandamiodaroneincardioversioninpatientswithparoxysmalatrialfibrillationandflutter AT aisalpagarova preliminaryresultsofaprospectiverandomizedstudycomparingtheefficacyandsafetyofrefralonandamiodaroneincardioversioninpatientswithparoxysmalatrialfibrillationandflutter AT lodulaev preliminaryresultsofaprospectiverandomizedstudycomparingtheefficacyandsafetyofrefralonandamiodaroneincardioversioninpatientswithparoxysmalatrialfibrillationandflutter AT dvpevzner preliminaryresultsofaprospectiverandomizedstudycomparingtheefficacyandsafetyofrefralonandamiodaroneincardioversioninpatientswithparoxysmalatrialfibrillationandflutter AT spgolitsyn preliminaryresultsofaprospectiverandomizedstudycomparingtheefficacyandsafetyofrefralonandamiodaroneincardioversioninpatientswithparoxysmalatrialfibrillationandflutter |